🇺🇸 Recombinant human follicle stimulating hormone in United States

43 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 20 April 2025 – 20 April 2026
• Total reports: 43

Most-reported reactions

1. Abortion — 10 reports (23.26%)
2. Ovarian Hyperstimulation Syndrome — 5 reports (11.63%)
3. Congenital Anomaly — 4 reports (9.3%)
4. Ectopic Pregnancy — 4 reports (9.3%)
5. Maternal Exposure During Pregnancy — 4 reports (9.3%)
6. Off Label Use — 4 reports (9.3%)
7. Abortion Spontaneous — 3 reports (6.98%)
8. Foetal Exposure During Pregnancy — 3 reports (6.98%)
9. Live Birth — 3 reports (6.98%)
10. Premature Baby — 3 reports (6.98%)

Source database →

Frequently asked questions

Is Recombinant human follicle stimulating hormone approved in United States?

Recombinant human follicle stimulating hormone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Recombinant human follicle stimulating hormone in United States?

University of California, San Diego is the originator. The local marketing authorisation holder may differ — check the official source linked above.